<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is characterized by peripheral blood cytopenias and risk of progression to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0003281'>Elevated serum ferritin</z:hpo> (SF), due to <z:hpo ids='HP_0010972'>ineffective erythropoiesis</z:hpo> and increased iron absorption from the gut, is often observed in non-transfused <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, suggesting involvement of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in its pathogenesis </plain></SENT>
<SENT sid="2" pm="."><plain>However, the prognostic value of the baseline SF is unclear </plain></SENT>
<SENT sid="3" pm="."><plain>We evaluated baseline SF levels in non-transfused <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>The SF level was significantly higher in the 47 MDS patients in this study than in the healthy controls (P &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>The SF level of higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (int-2/high) was significantly higher than that of the lower-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (low/int-1) (467 ± 354 vs. 277 ± 372 ng/ml, P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>The SF level in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with chromosomal abnormality was significantly higher than that in patients with <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype </plain></SENT>
<SENT sid="7" pm="."><plain>When patients were divided into the low SF group (&lt;500 ng/ml) and high SF group (≥500 ng/mL), the survival time was significantly longer in the former group than the latter group (118.8 vs. 10.2 M, P = 0.002) </plain></SENT>
<SENT sid="8" pm="."><plain>Further, <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e>) was significantly longer in the low SF group than the high SF group (P = 0.010) </plain></SENT>
<SENT sid="9" pm="."><plain>Baseline SF level may, therefore, be a prognostic factor for overall survival and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>